Miao‐Zhen Qiu

Closest collaborators

The 18 strongest of 18 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

1. Yuhong Li · 5 shared papers, 2012–2024 · strength 0.34
   • Paper Phase II study of SOXIRI (S-1/oxaliplatin/irinotecan) chemotherapy in patients with unresectable pancreatic ductal aden… DOI 10.1016/j.pan.2023.12.008↗
   • Paper Pathologic Diagnosis of Pancreatic Adenocarcinoma in the United States: Its Status and Prognostic Value. DOI 10.7150/jca.14185↗
   • Paper Phase I/II study of albumin-bound nab-paclitaxel plus gemcitabine administered to Chinese patients with advanced pancre… DOI 10.1007/s00280-013-2102-4↗
2. Feng‐Hua Wang · 4 shared papers, 2012–2024 · strength 0.31
   • Paper Phase II study of SOXIRI (S-1/oxaliplatin/irinotecan) chemotherapy in patients with unresectable pancreatic ductal aden… DOI 10.1016/j.pan.2023.12.008↗
   • Paper Pathologic Diagnosis of Pancreatic Adenocarcinoma in the United States: Its Status and Prognostic Value. DOI 10.7150/jca.14185↗
   • Paper The status of HBV infection influences metastatic pattern and survival in Chinese patients with pancreatic cancer. DOI 10.1186/1479-5876-11-249↗
3. Dajun Yang · 1 shared paper, 2026 · strength 0.27
   • Paper Olverembatinib, a novel BCR-ABL tyrosine kinase inhibitor, exhibits anti-tumor activity and synergizes with gemcitabine… DOI 10.1038/s41698-026-01489-9↗
4. Zengfei Xia · 1 shared paper, 2026 · strength 0.27
   • Paper Olverembatinib, a novel BCR-ABL tyrosine kinase inhibitor, exhibits anti-tumor activity and synergizes with gemcitabine… DOI 10.1038/s41698-026-01489-9↗
5. Dongsheng Zhang · 3 shared papers, 2012–2024 · strength 0.25
   • Paper Clinical sonochemotherapy of inoperable pancreatic cancer using diagnostic ultrasound and microbubbles: a multicentre, … DOI 10.1007/s00330-023-10210-4↗
   • Paper Pathologic Diagnosis of Pancreatic Adenocarcinoma in the United States: Its Status and Prognostic Value. DOI 10.7150/jca.14185↗
   • Paper ABO blood group, hepatitis B viral infection and risk of pancreatic cancer. DOI 10.1002/ijc.26376↗
6. Xujia Li · 1 shared paper, 2024 · strength 0.20
   • Paper Phase II study of SOXIRI (S-1/oxaliplatin/irinotecan) chemotherapy in patients with unresectable pancreatic ductal aden… DOI 10.1016/j.pan.2023.12.008↗
7. Shengping Li · 1 shared paper, 2024 · strength 0.20
   • Paper Phase II study of SOXIRI (S-1/oxaliplatin/irinotecan) chemotherapy in patients with unresectable pancreatic ductal aden… DOI 10.1016/j.pan.2023.12.008↗
8. Guifang Guo · 1 shared paper, 2024 · strength 0.20
   • Paper Phase II study of SOXIRI (S-1/oxaliplatin/irinotecan) chemotherapy in patients with unresectable pancreatic ductal aden… DOI 10.1016/j.pan.2023.12.008↗
9. Qi Quan · 1 shared paper, 2024 · strength 0.20
   • Paper Phase II study of SOXIRI (S-1/oxaliplatin/irinotecan) chemotherapy in patients with unresectable pancreatic ductal aden… DOI 10.1016/j.pan.2023.12.008↗
10. Rui‐Hua Xu · 5 shared papers, 2012–2016 · strength 0.18
    • Paper Pathologic Diagnosis of Pancreatic Adenocarcinoma in the United States: Its Status and Prognostic Value. DOI 10.7150/jca.14185↗
    • Paper Phase I/II study of albumin-bound nab-paclitaxel plus gemcitabine administered to Chinese patients with advanced pancre… DOI 10.1007/s00280-013-2102-4↗
    • Paper The status of HBV infection influences metastatic pattern and survival in Chinese patients with pancreatic cancer. DOI 10.1186/1479-5876-11-249↗
11. Zheng Liu · 1 shared paper, 2024 · strength 0.17
    • Paper Clinical sonochemotherapy of inoperable pancreatic cancer using diagnostic ultrasound and microbubbles: a multicentre, … DOI 10.1007/s00330-023-10210-4↗
12. Feng Han · 1 shared paper, 2024 · strength 0.17
    • Paper Clinical sonochemotherapy of inoperable pancreatic cancer using diagnostic ultrasound and microbubbles: a multicentre, … DOI 10.1007/s00330-023-10210-4↗
13. De‐Shen Wang · 4 shared papers, 2012–2016 · strength 0.15
    • Paper Pathologic Diagnosis of Pancreatic Adenocarcinoma in the United States: Its Status and Prognostic Value. DOI 10.7150/jca.14185↗
    • Paper Phase I/II study of albumin-bound nab-paclitaxel plus gemcitabine administered to Chinese patients with advanced pancre… DOI 10.1007/s00280-013-2102-4↗
    • Paper Comparison of the prognostic values of various inflammation based factors in patients with pancreatic cancer. DOI 10.1007/s12032-012-0226-8↗
14. Dong-sheng Zhang · 3 shared papers, 2012–2013 · strength 0.10
    • Paper Phase I/II study of albumin-bound nab-paclitaxel plus gemcitabine administered to Chinese patients with advanced pancre… DOI 10.1007/s00280-013-2102-4↗
    • Paper The status of HBV infection influences metastatic pattern and survival in Chinese patients with pancreatic cancer. DOI 10.1186/1479-5876-11-249↗
    • Paper Comparison of the prognostic values of various inflammation based factors in patients with pancreatic cancer. DOI 10.1007/s12032-012-0226-8↗
15. Feng Wang · 1 shared paper, 2016 · strength 0.05
    • Paper Pathologic Diagnosis of Pancreatic Adenocarcinoma in the United States: Its Status and Prognostic Value. DOI 10.7150/jca.14185↗
16. Xiaoli Wei · 1 shared paper, 2013 · strength 0.03
    • Paper The status of HBV infection influences metastatic pattern and survival in Chinese patients with pancreatic cancer. DOI 10.1186/1479-5876-11-249↗
17. Feng Wang · 1 shared paper, 2013 · strength 0.03
    • Paper The status of HBV infection influences metastatic pattern and survival in Chinese patients with pancreatic cancer. DOI 10.1186/1479-5876-11-249↗
18. Zhi‐Qiang Wang · 1 shared paper, 2012 · strength 0.03
    • Paper ABO blood group, hepatitis B viral infection and risk of pancreatic cancer. DOI 10.1002/ijc.26376↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.